Company / Operating Margin
Matinas BioPharma Holdings, Inc. Operating Margin History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-771.3%
FY2023
5-year range
-74954.5% / -771.3%
FY2019-FY2023
Trend
+99.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -74954.5% to -771.3% over the past 2 years.
Based on SEC 10-K filings.
-771.3% in FY2023 with a 5-year CAGR of +10253.3%.
Improved from -74954.5% to -771.3% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- +14517.1pp
- 5-Year Change
- +10253.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, operating margin increased 99.0% year-over-year.
- Lowest operating margin in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -771.3% | +99.0% |
| FY2022 | -74954.5% | +0.0% |
| FY2021 | -74954.5% | -390.3% |
| FY2020 | -15288.4% | -25.0% |
| FY2019 | -12230.9% | -10.9% |
| FY2018 | -11024.6% | -116.3% |
| FY2017 | -5096.0% | - |
| FY2016 | - | - |
| FY2015 | -5096.0% | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026